• Explore /
  • Poster
  • / Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).

Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).

Abstract Video & Slides Poster

Authors

Umberto Vitolo

Umberto Vitolo

Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy

Umberto Vitolo , Michele Merli , Lalita Norasetthada , Timothy Robert Wassenaar , Eva Maria Donato Martín , Sabela Bobillo , Biyi Shen , Dina M Flink , Min Zhu , Soujanya Chandrasekharan , Jurriaan Brouwer-Visser , Aafia Chaudhry , Hesham Mohamed , Srikanth R Ambati , Raul Cordoba

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT06149286

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS7094)

DOI

10.1200/JCO.2024.42.16_suppl.TPS7094

Abstract #

TPS7094

Poster Bd #

71b

Abstract Disclosures

Similar Posters

First Author: Ruemu Ejedafeta Birhiray

First Author: Laurie Helen Sehn

First Author: Andrew David Zelenetz

First Author: Loretta J. Nastoupil